The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation

• Published in: Molecular immunology Vol. 44; no. 12; pp. 3162 - 3167
• Main Authors: Kavanagh, D., Burgess, R., Spitzer, D., Richards, A., Diaz-Torres, M.L., Goodship, J.A., Hourcade, D.E., Atkinson, J.P., Goodship, T.H.J.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2007
• Subjects: CD55 Antigens - genetics; Complement; Complement Factor H - genetics; Complement System Proteins - genetics; Decay accelerating factor (DAF); DNA Mutational Analysis; Escherichia coli; Factor H (CFH); Factor I (CFI); Family Health; Fibrinogen; Hemolytic uremic syndrome; Hemolytic-Uremic Syndrome - etiology; Hemolytic-Uremic Syndrome - genetics; Humans; Membrane cofactor protein (MCP); Membrane Cofactor Protein - genetics; Models, Molecular; Mutation; Mutation, Missense; Factor I (CFI); Membrane cofactor protein (MCP); Complement; Hemolytic uremic syndrome; Decay accelerating factor (DAF); Factor H (CFH)
• ISSN: 0161-5890; 1872-9142
• DOI: 10.1016/j.molimm.2007.01.036

Hemolytic uremic syndrome is the clinical triad of thrombocytopenia, microangiopathic hemolytic anaemia and acute renal failure. Cases not associated with a preceding Shiga-like toxin producing Escherichia coli are described as atypical HUS (aHUS). Approximately 50% of patients with aHUS have mutations in one of three complement regulatory proteins, Factor H ( CFH), membrane cofactor protein ( MCP;CD46) or factor I ( IF). A common feature of these three proteins is that they regulate complement by cofactor activity. Decay accelerating factor (DAF; CD55) regulates the complement system by disassociating the alternative and classical pathway convertases. Like CFH and MCP, the gene for DAF lies within the regulators of complement activation (RCA) gene cluster at 1q32. In 1998, we described linkage to this region in families with aHUS which led to the discovery of mutations in CFH and MCP. We therefore genotyped DAF in a panel of 46 aHUS patients including families with linkage to the RCA cluster. A mutation, I197V, was identified in one patient with familial HUS which was not found in 100 healthy controls. Molecular modelling of this mutation shows that the I197V mutation does not reside in an area which would be predicted to be important in decay accelerating activity. The expression of I197V on EBV-transformed B lymphocytes was equivalent to that of wild type controls. There was no significant decrease in decay acceleration activity of the recombinantly produced I197V mutant compared with wild type, as measured by a complement-mediated lytic assay. In conclusion, this study, identifies only one mutation in DAF in 46 patients with aHUS. This mutation, I197V, does not impair complement regulation and cannot be implicated in the pathogenesis of aHUS in this patient. This suggests that the complement regulatory abnormality in aHUS is principally one of deficient cofactor activity rather than of decay acceleration activity.